EDESA BIOTECH, INC. Net Fee Amt
EDESA BIOTECH, INC. (EDSA) had Net Fee Amt of $784.52 as of 2026-07-01, per its S-3 filed 2026-07-02.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-02
- 2026-07-01: Net Fee Amt $784.52.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-01 | $784.52 S-3 · filed 2026-07-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |